Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials

TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on July 30.

Tara Bancroft’s rating is based on several strategic developments and ongoing trials at Fate Therapeutics. The company is focusing on its CAR-iT programs, particularly FT819, which is currently in a Phase I trial for systemic lupus erythematosus (SLE). The trial is expanding to include additional B-cell autoimmune conditions, and the potential for a rapid progression to a registrational study could be on the horizon if the regulatory milestones are met.
Despite these promising developments, the Hold rating reflects a cautious stance due to the early stage of clinical trials and the need for further data to establish efficacy and safety. While initial results from the first three SLE patients treated with FT819 are encouraging, with notable improvements in disease activity, the long-term outcomes and broader applicability of the treatment remain to be seen. The ongoing dose escalation and expansion efforts are critical to determining the optimal dosing strategy for future studies.

In another report released on July 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.